Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

BACKGROUND: Immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells is effective in some hematologic tumors. In solid tumors, however, sustained antitumor responses after CAR T-cell therapy remain to be demonstrated both in the pre-clinical and clinical setting. A perceived barrier to...

Descripción completa

Detalles Bibliográficos
Autores principales: Stüber, Tanja, Monjezi, Razieh, Wallstabe, Lars, Kühnemundt, Johanna, Nietzer, Sarah Louise, Dandekar, Gudrun, Wöckel, Achim, Einsele, Hermann, Wischhusen, Jörg, Hudecek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204619/
https://www.ncbi.nlm.nih.gov/pubmed/32303620
http://dx.doi.org/10.1136/jitc-2020-000676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204619/
https://www.ncbi.nlm.nih.gov/pubmed/32303620
http://dx.doi.org/10.1136/jitc-2020-000676

Ejemplares similares